Literature DB >> 12522089

In vitro evidence for the presence of [3H]-haloperidol uptake in rat brain.

Stefania Ruiu1, Giorgio Marchese, Pier Luigi Saba, Rosalba Satta, GianLuigi Gessa, Andrea Vaccari, Luca Pani.   

Abstract

1 The neuroleptic [(3)H]-haloperidol (HP) was taken up in synaptosomes prepared from rat brain, in a temperature-, sodium ion-, and energy-dependent process. 2 The highest concentration of uptake sites (V(max)=2.37 pmol mg(-1) protein min(-1)) was in the striatum with the other brain areas displaying lower (by 50-70%) values. 3 The affinity values (K(m) approximately equal to 40 nM) were similar in all brain areas considered. 4 The pharmacological characterization did not indicate a well-defined group of inhibitors, which suggested that HP might not use a transporter for recognized neurotransmitters. 5 The HP metabolites tested, including HPTP, were competitive inhibitors of [(3)H]-HP uptake, an indirect indication that they may actively enter the striatal nerve endings through the same carrier. 6 Since the uptake process was partially affected by the incubation of [(3)H]-HP in the presence of several antagonists of HP-transforming cytochrome P450 isoforms, the binding of HP at some enzyme sites inside the synaptosome cannot be excluded. 7 In conclusion, the present results suggest that HP may be actively transported in the rat brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522089      PMCID: PMC1573635          DOI: 10.1038/sj.bjp.0705009

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Further characterisation of the interaction of haloperidol metabolites with neurotransmitter transporters in rat neuronal cultures and in transfected COS-7 cells.

Authors:  G A Siebert; S M Pond; L J Bryan-Lluka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-03       Impact factor: 3.000

2.  Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.

Authors:  Giorgio Marchese; Maria Antonietta Casu; Francesco Bartholini; Stefania Ruiu; Pierluigi Saba; Gian Luigi Gessa; Luca Pani
Journal:  Eur J Neurosci       Date:  2002-04       Impact factor: 3.386

3.  MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.

Authors:  H Rollema; M Skolnik; J D'Engelbronner; K Igarashi; E Usuki; N Castagnoli
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

4.  Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.

Authors:  K Igarashi; F Kasuya; M Fukui; E Usuki; N Castagnoli
Journal:  Life Sci       Date:  1995-11-17       Impact factor: 5.037

5.  In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783.

Authors:  J M Vaugeois; J J Bonnet; J Costentin
Journal:  Eur J Pharmacol       Date:  1992-01-07       Impact factor: 4.432

6.  Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue.

Authors:  E M Clement; D G Grahame-Smith; J M Elliott
Journal:  Neuropharmacology       Date:  1998-07       Impact factor: 5.250

7.  Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.

Authors:  B Subramanyam; H Rollema; T Woolf; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

Review 8.  Tardive dyskinesia.

Authors:  J Gerlach; D E Casey
Journal:  Acta Psychiatr Scand       Date:  1988-04       Impact factor: 6.392

9.  1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies.

Authors:  J Bloomquist; E King; A Wright; C Mytilineou; K Kimura; K Castagnoli; N Castagnoli
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

10.  Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin.

Authors:  K Sriram; K S Pai; V Ravindranath
Journal:  J Neurochem       Date:  1995-03       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.